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Abstract
Background: Current tools for the diagnosis of tuberculosis pleural effusions are sub-optimal. Data about the value of new
diagnostic technologies are limited, particularly, in high burden settings. Preliminary case control studies have identified
IFN-c-inducible-10kDa protein (IP-10) as a promising diagnostic marker; however, its diagnostic utility in a day-to-day clinical
setting is unclear. Detection of LAM antigen has not previously been evaluated in pleural fluid.
Methods: We investigated the comparative diagnostic utility of established (adenosine deaminase [ADA]), more recent
(standardized nucleic-acid-amplification-test [NAAT]) and newer technologies (a standardized LAM mycobacterial antigen-
detection assay and IP-10 levels) for the evaluation of pleural effusions in 78 consecutively recruited South African
tuberculosis suspects. All consenting participants underwent pleural biopsy unless contra-indicated or refused. The
reference standard comprised culture positivity for M. tuberculosis or histology suggestive of tuberculosis.
Principal Findings: Of 74 evaluable subjects 48, 7 and 19 had definite, probable and non-TB, respectively. IP-10 levels were
significantly higher in TB vs non-TB participants (p,0.0001). The respective outcomes [sensitivity, specificity, PPV, NPV %]
for the different diagnostic modalities were: ADA at the 30 IU/L cut-point [96; 69; 90; 85], NAAT [6; 93; 67; 28], IP-10 at the
28,170 pg/ml ROC-derived cut-point [80; 82; 91; 64], and IP-10 at the 4035 pg/ml cut-point [100; 53; 83; 100]. Thus IP-10,
using the ROC-derived cut-point, missed ,20% of TB cases and mis-diagnosed ,20% of non-TB cases. By contrast, when a
lower cut-point was used a negative test excluded TB. The NAAT had a poor sensitivity but high specificity. LAM antigen-
detection was not diagnostically useful.
Conclusion: Although IP-10, like ADA, has sub-optimal specificity, it may be a clinically useful rule-out test for tuberculous
pleural effusions. Larger multi-centric studies are now required to confirm our findings.
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Introduction
Annually, over half a million pleural effusions are diagnosed
world-wide and it is one of the commonest forms of extra-pulmonary
tuberculosis (TB; [1]). In Africa, where TB is out of control,
extrapulmonary TB is more common due to HIV co-infection. The
diagnosis of TB pleural effusion is challenging. Pleural biopsy has a
good yield (,80%) but it is invasive, expensive and requires trained
medical personnel [2]. Smear microscopy of pleural fluid had a
dismal yield (,5%) and culture takes several weeks to obtain [2].
Other rapid diagnostic tools such as nucleic acid amplification tests
(NAAT) have poor sensitivity in pleural fluid (,50%; [3]), though
the performance outcomes of a standardized NAAT has not
previously been evaluated in a high HIV sero-prevalence setting
[3]. Given the drawbacks of existing tools investigators have pursued
the detection of measurable biomarkers, including IFN-c levels [4]
and adenosine-deaminase (ADA), as diagnostic adjuncts [2].
However, measuring IFN-c is relatively expensive in high burden
settings [5] and ADA is not widely available in clinical laboratories,
and is non-specific even in high burden settings [2,6].
An alternative promising, but poorly studied, biomarker is IFN-
c inducible protein of 10 kDa (IP-10). IP-10, a Th1-associated
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chemokine, was found to be a useful discriminatory tool in three
case-controlled studies [7,8,9] but its clinical diagnostic utility in
an unselected cohort of TB suspects is unknown. More recently,
lipoarabinomannan (LAM) antigen detection was found to be
useful for the diagnosis of TB when using urine obtained from
Tanzanian TB suspects [10]. However, the utility of a standard-
ized LAM antigen-capture ELISA assay (ClearviewH TB ELISA)
has not previously been evaluated in other body compartments
including pleural fluid.
In this study we prospectively evaluated the comparative
diagnostic utility of established (adenosine deaminase [ADA]),
more recent (standardized nucleic-acid-amplification-test
[NAAT]) and newer technologies (IP-10 levels and a standard-
ized LAM mycobacterial antigen-detection assay) for the
evaluation of pleural effusions in 78 South African tuberculosis
suspects. The gold standard for tuberculosis was culture
positivity for M. tuberculosis and/ or histology in keeping with
tuberculosis.
Methods
Patient recruitment, characterization and routine
laboratory tests
Seventy-eight consecutive patients with suspected TB pleural
effusion (persistent fever, night sweats or cough, chest pain, loss of
weight, previous tuberculosis or recent TB contact, or any patient
in whom, due to suggestive symptoms or signs, TB was part of the
differential diagnosis) were prospectively recruited at the Groote
Schuur, Somerset and Victoria hospitals in Cape Town, South
Africa, after informed consent (see figure 1 for an overview of the
study plan), over a 12 month period (ending 30 April 2008). Those
under 18 years of age, pregnant or refusing consent were not
recruited. The data presented here is part of a parent study, which
evaluated the role of unstimulated IFN-c versus quantitative T cell
responses for the diagnosis of TB pleural effusion. Four patients
were excluded for other reasons and thus there were 74 patients
with evaluable results (figure 1). Study approval was obtained from
Figure 1. Summary and flow chart of the established and newer technologies evaluated.
doi:10.1371/journal.pone.0004689.g001
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the University of Cape Town Health Sciences Faculty research
ethics committee.
All patients had a history taken, detailed physical examination
performed, routine haemtological investigations, including testing
for HIV infection, chest x-ray, sputum examination when possible
(fluorescent microscopy for acid fast bacilli and mycobacterial
culture using the MGIT 960 system), and aspiration of
approximately 20 ml of pleural fluid (or closest obtainable volume)
for biochemical (protein and glucose), cytological (for malignant
cells, cell differential [Dif-Quick, American Scientific products]),
and microbiological (Gram stain and culture for bacterial
pathogens, mycobacterial fluorescence microscopy and culture
for M. tuberculosis using the MGIT 960 system) evaluation.
For accurate characterization of disease multiple closed pleural
biopsies (approximately four) were undertaken using an Abra-
ham’s needle under local anesthesia, by a trained internal
medicine resident (specialist registrar). In 16 patients biopsies
were not performed because of patient refusal, a contra-indication
or a positive culture of fluid, or histology from another site, prior to
attempted pleural biopsy. The reference standard for tuberculosis
was culture positivity for M. tuberculosis and/ or histology in
keeping with tuberculosis (caseous necrosis or acid fast bacilli with
or without granuloma formation). Patients were thus characterized
as (i) definite TB: either positive M.tb culture (sputum, pleural fluid
or tissue) and/ or histology in keeping with tuberculosis, and a
clinico-radiological picture consistent with TB with clinical
response to anti-TB treatment; (ii) non-TB: alternative diagnosis
made on histology or pleural fluid aspiration, and not treated for
TB, and on 3 to 6 month follow-up there were no features to
suggest TB, and (iii) probable TB: clinical picture of TB but not
satisfying the definite TB criteria and treated for TB by the
attending physician.
ADA, LAM antigen-detection, NAAT and IP-10 levels
Pleural fluid protein and ADA levels were derived using the
Biuret and colorimetric methods, respectively. LAM antigen
concentration in the pleural fluid was measured in duplicate, after
a heating step to dissociate antigen and antibody, according to the
manufacturer’s instructions (ClearviewH TB ELISA, ME, USA; see
http://www.clearview.com/tb_elisa.aspx). An interim analysis
was done in the 1st 24 recruited patients (14 definite or probable
TB cases and 10 non-TB cases) to use a go/ no-go decision point
for further LAM testing. For nucleic-acid-amplification the
Amplified Tuberculosis Direct Test (Genprobe, San Diego, CA)
was performed in duplicate according to the manufacturer’s
instructions (H37Rv served as a positive control and M.
intracellulare served as the negative control) and readouts were
obtained using a Leader 50 Luminometer (Genprobe, San Diego,
CA).
IP-10 levels were measured, according to the manufacturer’s
instructions, using a standardized Human IP-10 ELISA Kit
(Hycult Biotechnology, Uden, The Netherlands). All assays were
performed by an experienced laboratory technician who was
blinded to patient and clinical details.
Bio-clinical score
To ascertain the relative value of newer tests in a high burden
setting, regression models were fitted to identify variables
independently associated with risk of tuberculosis, taking into
account findings from the history, physical examination and
pleural fluid biochemical data. The final bio-clinical scoring rule,
incorporating age and protein levels, was developed by assigning a
relative score or points to each of the variables included in the final
multivariate model. Here we use the model to evaluate the relative
incremental value of the different pleural diagnostic tests.
Statistical analysis
Categorical variables were compared using the x2 test or Fisher
exact test and continuous variables were compared using t-student
test, whenever appropriate. Non-parametric tests (Mann-Whitney)
were used for non-normally distributed variables. Concordance
between tests was measured using the kappa co-efficient.
Diagnostic accuracy, including 95% confidence intervals, was
assessed using sensitivity, specificity, predictive values and area
under the ROC in the TB and non-TB sub-groups. The study
report was prepared using the Standards for Reporting of
Diagnostic Accuracy (STARD initiative) format (19).
Results
Demographic, clinical and biochemical data
A summary of the study plan is shown in figure 1. Of the 78
patients recruited 4 were excluded from the analysis (one because
of a coagulated sample, one because an incorrect sample had been
harvested [ascitic instead of pleural fluid], and two due to
unverifiable patient details). Thus 74 patients had results for
pleural fluid microscopy, biochemistry, ADA, PCR or IP-10 levels.
There were 48, 19 and 7 patients with definite, non-TB and
probable TB, respectively. Effusions in the non-TB group were
due to several causes (2 lymphoma, 2 myeloproliferative disorders,
9 adeno or small cell carcinoma, 3 parapneumonic, and 3 due to
other causes).
Of those tested 20/51 (49%) were HIV positive. In the TB vs
non-TB group the mean age (years) was significantly lower (37
vs 55, respectively; p,0.0001) though there were more people
of Black African and mixed race (48 vs 19, respectively;
p = 0.03). There was no significant inter-group difference for
sex, HIV status, BCG vaccination or employment status. The
mean (SD) pleural fluid protein levels were significantly higher
in the TB vs non-TB group [58.9(15.7) vs 43.4(18.5),
respectively; p = 0.003]. In the final multivariate logistic
regression model, age (,42 years), [odds ratio (OR) = 3.89,
95% CI 1.01–14.90, p = 0.04] and protein levels (.53 g/L)
[OR= 3.59, 95% CI 1.02–12.56, p = 0.04) were independently
associated with the risk of tuberculosis. These variables, when
incorporated into a bio-clinical score, had a maximal sensitivity
and specificity of 54 and 89%. The median (25th; 75th
percentiles) pleural fluid cell count was 1.756106 cells/ml
(1.03; 5.456106 cells/ml) and the median volume of fluid
obtained was 20 ml (10; 25 ml).
Results of smear, culture, histology and NAAT
Smear, pleural fluid culture, and biopsy (tissue culture and
histology) were positive in 1, 27 and 41 of the 48 definite TB cases,
respectively, and by definition, in none of the non-TB cases. None
of the probable TB cases were culture or biopsy positive but all
were treated empirically for TB based on clinical suspicion.
Twenty one percent (16/ 74) of patients did not have a pleural
biopsy (refused by 4 patients, contra-indicated in 2 patients, 1 in
whom a liver biopsy was done, and 9 in whom the culture result
was positive prior to a biopsy being done [6 sputum culture
positive and 3 pleural fluid culture positive]). The diagnostic
outcomes of protein levels at different cut-points is shown in
table 1. Performance outcomes of the NAAT (manufacturer-
derived cut-point) were poor and are shown in table 1, table 2 and
figure 2.
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IP-10 and ADA
The IP-10 scatter-plot (n= 73) and area under the ROC is shown
in figure 3 and performance outcomes are shown in table 1. At an
AUC-derived cut-point of 28170 pg/ml (definite vs non-TB) the
sensitivity (%), specificity, +LR (likelihood ratio) and 2ve LR (95%
CI) was 80 (64; 91), 82 (57; 97), 4.53 (2.32; 8.85) and 0.24 (0.19;
0.32), respectively, and the area under the ROC curve was 0.82. By
contrast, at a lower cut-point of 4035 pg/ ml (derived from the ROC
for the best NPV) the sensitivity was 100 (91; 100), specificity 53 (31;
74), NPV (100; 71; 100), +LR 2.13 (1.66; 2.72) and2ve LR 0 (0; 0),
Table 1. Performance outcomes of ADA, microbiological investigations, a nucleic-acid-amplification-test [NAAT] and unstimulated
IFN-c levels for the diagnosis of TB pleural effusion in 74 TB suspects using the definite and non-TB groups.
Cut-point Sens % Spec % PPV % NPV % Accuracy AUC
Maximum clinical score n/a 54 (40; 67) 89 (68;97) 92 (77; 98) 43 (29;59) 64 (52;74) n/a
Protein .30 g/l** 94 (83;98) 12 (3; 34) 75 (62; 84) 40 (12; 77) 72 (60; 81) 0.72
.60 g/l*** 46 (33; 60) 94 (78; 99) 94 (79; 99) 39 (26; 54) 59 (47; 70)
ADA .30 iu/l** 96 (86; 99) 69 (44; 86) 90 (78; 96) 85 (58; 96) 89 (78; 94) 0.93
.47 iu/l*** 91 (80; 98) 94 (72; 99) 98 (85; 99) 79 (57; 92) 92 (82; 97)
.13 iu/l# 100 (92;100) 38 (19;62) 82 (70;90) 100 (61;100) 84 (73;91)
NAAT 30 000 RLU 6 (2;18) 93 (69.99) 67 (9;91) 28 (17;42) 29 (18;42) 0.50
IP-10 28170 pg/ml*** 80 (64; 91) 82 (57; 97) 91 (78;97) 64 (43;80) 81 (69;89) 0.82
IP-10 4035 pg/ml# 100 (91;100) 53 (31;74) 83 (70;91) 100 (71;100) 86 (75;93) 0.77
( ; ) = 95% CI.
**Cut-point used in day-to-day clinical practice in Cape Town, South Africa, where the test guides the institution of anti-TB treatment.
AUC= area under the ROC curve.
***AUC-derived cut-point.
#cut-point with a high NPV.
RLU= relative light units detectable using a luminometer.
doi:10.1371/journal.pone.0004689.t001
Table 2. Performance outcomes of ADA, microbiological investigations, a nucleic-acid-amplification-test [NAAT] and unstimulated
IFN-c levels for the diagnosis of TB pleural effusion in 74 TB suspects when the definite and probable TB groups are combined.
Cut-point Sens % Spec % PPV % NPV % Accuracy AUC
Maximum clinical score n/a 52 94 97 38 62 67
39;65 73;99 83;99 25;53 50;72
Protein .30 g/l** 94 18 79 50 76 0.72
(85;98) (6;41) (67;87) 19;81 (65;85)
.60 g/l*** 44 94 79 35 56
(32;58) (73;99) (81;99) (23;49) 45;67
ADA .30 iu/l** 94 65 89 79 87 0.94
85;98 41;83 79;95 52;92 77;93
.47 iu/l*** 89 65 80 71 78
77;95 41;83 68;88 50;86 67;85
.13 iu/l# 100 35 83 100 84
93;100 17;59 52;90 61;100 74;91
NAAT 30 000 RLU 7 93 75 26 29 0.49
3; 19 69;99 30;95 16;39 19;42
IP-10 28170 pg/ml# 79 83 92 61 80 0.82
(63;89) (59;94) (79;97) (41;78) (68;88)
IP-10 100 53 83 100 86 0.77
4035 pg/ml# (91;100) (31;74) (70;91) (71;100) (75;93)
( ; ) = 95% CI.
**Cut-point used in day-to-day clinical practice in Cape Town, South Africa, where the test guides the institution of anti-TB treatment.
AUC= area under the ROC curve.
***AUC-derived cut-point.
#cut-point with a high NPV.
RLU= relative light units detectable using a luminometer.
doi:10.1371/journal.pone.0004689.t002
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respectively. Also shown are the outcomes when the probable TB
cases were included in the analysis. HIV status did not impact on IP-
10 or NAAT test results (data not shown).
By contrast the ADA (30 iu/l cut-point) had a sensitivity of 96
(86; 99), specificity 69 (44; 86), NPV 85 (58; 96), +LR 17.4 (2.44;
124.1), and2ve LR 0.09 (0.05; 0.15), respectively. At the cut-point
used for clinical decision making in Cape Town (30 iu/l) ADA had
a sub-optimal specificity of 64% compared to a higher AUC-
derived cut-point (47 iu/l; table 1, table 2).
LAM antigen
We measured LAM antigen levels (ClearviewH TB ELISA, ME,
USA) in the first 22 TB suspects recruited (12 TB, 2 probable TB
and 10 non-TB). The sensitivity of LAM antigen was 8% (1 of 12
patients) and specificity was 100%.
Incremental diagnostic value of different tests
Incremental test value is summarised in table 3. ADA and IP-10
(at both cut-points) was more sensitive than the clinical evaluation
alone, though histology did not add any further value. Adding IP-
10 to ADA had little incremental benefit, however, at the lower IP-
10 cut-point the % NPV (95% CI) improved from 79 (57; 92) for
ADA alone, and 82 (59; 94) for ADA +IP-10, to 100 (71; 100).
Discussion
The diagnostic yield of current tools for pleural effusion is sub-
optimal. In this study we evaluated IP-10 and LAM antigen
detection against other tools for the diagnosis of TB pleural
effusion. Although IP-10 levels were significantly higher in TB
compared to non-TB patients it was not clinically useful because of
the sub-optimal specificity in the non-TB group. In three case
control studies, two immunological [8,9] and one diagnostic [7],
IP-10 levels were significantly higher in the TB compared to the
control group. In the only study reporting diagnostic outcomes in
11 TB patients [7], IP-10 discriminated well between TB and
malignant PE, and performed as well as unstimulated IFN-c (AUC
of 0.93 vs 0.99, respectively). Comparatively, although we found
Figure 3. Scatter-plot (left panel) showing IP-10 levels in patients with pleural tuberculosis versus non-tuberculosis controls. The
area under the ROC curve was 0.82.
doi:10.1371/journal.pone.0004689.g003
Figure 2. Scatter-plots (left panel) and area under the ROC (right panel) of a standardized nucleic-acid amplification test using
pleural fluid from patients with tuberculous (TB) and non-tuberculous (non-TB) effusions. Area under the ROC values are shown in
table 1. Positive (culture and amplification) and negative controls (culture and amplification) from 6 independent runs are shown.
doi:10.1371/journal.pone.0004689.g002
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highly significant inter-group differences (TB vs non-TB;
p,0.0001;), IP-10 missed the diagnosis in ,20% of TB patients
and was falsely positive in ,20% of non-TB patients using the
AUC-derived cut-point. Thus, IP-10 was not a meaningful clinical
discriminatory tool and levels were highly variable in patients with
malignant and para-pneumonic effusions.
IP-10 is an IFN-c-driven chemokine and a non-specific Th1
inflammatory marker and thus can be elevated in other disorders
including pulmonary fibrosis [11], multiple sclerosis [12] and
lymphoma [13]. It is also well recognized that case control studies,
though useful for preliminary screening evaluation of new
biomarkers, tends to overestimate diagnostic performance out-
comes [14]. Moreover, statistical inter-group difference, as we
demonstrate, does not necessary imply clinical usefulness. By
contrast, at the lower cut-point the IP-10 NPV was 100%, and the
negative LR was 0.24, making it a promising rule out test. This
may be useful in clinical practice, particularly in undiagnosed
pleural effusions when the histology is non-specific or non-
representative of pleural tissue. In this context a negative IP-10 test
may prompt a more vigorous search for other pathologies (e.g.
using alternative diagnostic strategies including thoracoscopy), and
reduce exposure to unwarranted or empiric anti-TB treatment and
its attendant toxicity.
By comparison the ADA (30 iu/l cut-point) had a better
sensitivity, PPV and positive LR, though the specificity and NPV
was sub-optimal implying that ,3 in 10 non-TB subjects would be
erroneously treated for TB and ,1 in 7 patients with a negative
test would in fact have TB. At a higher cut-point (47 iu/l) the
former misdiagnosis would be reduced, but not eliminated, and at
the expense of missing ,1 in 10 TB cases. At the lower cut-point
ADA would be an excellent rule-out test but specificity would be
poor. Nevertheless, ADA is cheaper and more widely available
than IP-10. Thus IP-10, which can be measured with several
commercially available ELISA assays, cannot replace ADA.
Rather, it could useful in a specific clinical context where ruling
out TB would be useful.
In the parent study using the same cohort of patients we show
that unstimulated IFN-c levels very accurately distinguishes TB
from non-TB effusions in African patients (data not shown). This
preliminary analysis showed a modest correlation between IP-10
and IFN-c levels (Spearman r= 0.3836). Why does IP-10, an IFN-
c inducible chemokine, not correlate highly with IFN-c levels, as it
does in peripheral blood [15]? IP-10 is also regulated by other
cytokines including IFN-a, IL-1b and IL-12 [16,17,18], disease
phenotype can modulate cytokine half-life [19], and there may be
differential cellular uptake and cellular regulation of IP-10 [17].
To meaningfully evaluate the relative clinical value IP-10 and
ADA we compared their utility to a simple bio-clinical score,
generated through regression analysis, and relevant to a resource-
poor setting [20,21]. Both IP-10 and ADA substantially improved
the sensitivity and NPV compared to bio-clinical assessment alone.
A combination of the clinical score with ADA improved the NPV
but not to an extent that was clinically useful. A combination of the
clinical score with IP-10, or IP-10 and ADA, added little
incremental value. At the lower IP-10 cut-point NPV was still
better than ADA at either cut-point (low or high). We also
investigated the effect of HIV status on test performance
outcomes. IP-10 levels were not significantly different in HIV+
and negative patients, though HIV+ patients were more likely to
have a positive pleural fluid culture (non-significant; data not
shown).
TB antigen detection has previously been investigated for its
diagnostic utility in pleural effusions. However, tuberculostearic
acid was found to have limited diagnostic utility [22]. More
recently, a preliminary study from Africa suggested that detection
of urinary LAM antigen was a useful diagnostic adjunct in TB
suspects [10]. The assay has now been commercialized into a
finalized prototype (see http://www.clearview.com/tb_elisa.aspx),
which we evaluated in pleural fluid. For cost-containment
purposes further testing of LAM was discontinued, after an
interim analysis of the first 24 patient results, because of its poor
diagnostic utility (only one out of 14 definite or probable TB cases
tested positive for LAM antigen). Why LAM antigen virtually
undetectable in pleural fluid? Preliminary experiments excluded
technical reasons and batch variability. To exclude the lack of
antigen-protein dissociation (pleural fluid has a high protein
content that may bind free LAM) a heating step was incorporated
into the test protocol to ensure dissociation. The lack of LAM
antigen detection in the majority of TB pleural effusions probably
reflects the pauci-bacillary nature of pleural disease, though high
affinity antigen-antibody binding cannot entirely be excluded.
The variability of NAAT performance outcomes are highly
dependant on laboratory protocols and we therefore evaluated a
standardized NAAT, hitherto not undertaken in an African
setting, in pleural TB suspects. The sensitivity of commercial
NAATs for pleural TB are highly variable (20 to 100%;
summarized in detail in [3,23]). Although, in our study, specificity
was high the sensitivity was poor (only 6%). Putative reasons may
Table 3. Individual and incremental value of different test combinations.
Combination Sens Spec PPV NPV accuracy
Clinical score$ 54 (40; 67) 89 (68; 97) 92 (77; 98) 43 (29; 59) 64 (52; 74)
Clinical score+histology 91 (78; 96) 63 (42; 78) 81 (86; 89) 79 (57; 92) 81 (69; 88)
Clinical score+ADA 96 (85; 99) 81 (60; 92) 92 (81; 97) 89 (89; 97) 91 (82; 96)
Clinical score+histology+ADA 92 (81; 97) 83 (61; 94) 94 (83; 98) 79 (57; 92) 89 (79; 95)
ADA* 91 (80; 98) 94 (72; 99) 98 (85; 99) 79 (57; 92) 92 (82; 97)
IP-10 80 (64; 91) 82 (57; 97) 91 (78;97) 64 (43;80) 81 (69;89)
IP-10 (4035 pg/ml cut-point) 100 (91;100) 53 (31;74) 83 (70;91) 100 (71;100) 86 (75;93)
IP-10 and clinical score 38 (25;52) 95 (73;99) 94 (74;99) 39 (26;53) 55 (49;66)
IP-10+ADA 93 (81; 98) 88 (64; 97) 95 (84; 99) 82 (59; 94) 91 (81; 96)
* = 47 iu/l cut-point and non-asterisked values refer to the 30 iu/l cut-point.
$ =maximal clinical score. Unless, otherwise stated all IP-10 outcomes refer to the 28170 pg/ml cut-point.
doi:10.1371/journal.pone.0004689.t003
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include the paucibaciliary nature of the disease, inhibitors in the
pleural fluid, and sub-optimal mycobacterial nucleic-acid extrac-
tion efficiency. The latter is less likely as a culture control (,10
organisms) was included in the experiment. However, the assay
used has no inhibitor-specific internal positive control. Further
studies are required to assess the impact of HIV-infection and
inhibitors on TB-specific nucleic acid amplification tests in high
burden settings.
We took several steps to minimize bias and ensure study
validity, including consecutive recruitment with universally applied
and pre-specified inclusion criteria, an experienced technician
blinded to clinical details, invasive procedures to ensure accurate
classification of patient and control sub-groups, and use of a pre-
specified reference standard. We also provide, through compar-
ison with clinical assessment and incremental test value over
existing tools, information on clinical utility rather than test
performance outcomes only (sensitivity, specificity etc; [24]). Thus,
there is an emphasis on ‘diagnostic’ rather than ‘test’ research. The
sensitivity of the test is compared to the sensitivity of clinical
assessment, which enables the incremental value of the test over
the clinician’s assessment, to be determined. Therefore, a test with
an apparently high sensitivity may have limited clinical utility if it
has little or no incremental benefit over clinical assessment. It is
also meaningful, for the purposes of determining value, to
determine the incremental benefit of a new test over an existing
one. Nevertheless, this study has several limitations. The sample
size was small and accuracy estimates relatively imprecise. We also
evaluated the test in the same population used to determine the
cut-points. Further work is now required to validate these cut-
points in different populations. Also, results are generalisable only
to high burden settings; further and larger studies are required to
evaluate whether outcomes are different in low burden settings.
For example, the high background rate of LTBI, host biological
factors and early TB infection may have impacted on test results.
In conclusion, like ADA, IP-10 levels at the AUC-derived cut-
point are not specific for tuberculosis, though at the lower cut-
point they appear to be promising rule-out tests for TB in a high
burden setting. Larger studies are required in other settings to
confirm these findings.
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